CN109350629B - Probiotic compound preparation for treating alcohol withdrawal syndrome and preparation method thereof - Google Patents
Probiotic compound preparation for treating alcohol withdrawal syndrome and preparation method thereof Download PDFInfo
- Publication number
- CN109350629B CN109350629B CN201811356719.3A CN201811356719A CN109350629B CN 109350629 B CN109350629 B CN 109350629B CN 201811356719 A CN201811356719 A CN 201811356719A CN 109350629 B CN109350629 B CN 109350629B
- Authority
- CN
- China
- Prior art keywords
- probiotic
- preparation
- alcohol
- withdrawal
- withdrawal syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the technical field of biology, and particularly relates to a probiotic compound preparation for treating alcohol withdrawal syndrome and a preparation method thereof. The preferable probiotics of the invention are common nonpathogenic dominant bacteria of human body, the bacteria can be planted in intestinal tracts of human body and proliferate in large quantity, the intestinal micro-ecological environment is improved by the action of dominant bacteria, biological antagonism, production of beneficial metabolite, direct stimulation of intestinal mucosa epithelium and the like, and the bacteria act on brain through 'intestine-brain-axis', thus achieving the purpose of relieving and treating alcohol dependence syndrome. The unique coating process can prolong the storage life of the activity of the probiotics, overcome the defect of short storage life of the conventional probiotic products, and effectively resist the influence of alcohol in vivo on the probiotics caused by drinking.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a probiotic compound preparation for treating alcohol withdrawal syndrome and a preparation method thereof.
Background
Drinking is a long and common life habit and social folk, but over-drinking can cause physical or mental damage and bring adverse social consequences. If the drinking time and the drinking amount reach a certain degree, the drinker cannot control the drinking behavior of the drinker and the symptoms of somatization and withdrawal appear, which are called alcohol dependence syndrome. The clinical manifestations are the patient's intense craving for alcohol, alcoholism and other symptoms. After abstinence from alcohol, the symptoms of tremor, hypodynamia, sweating, hyperreflexia, gastrointestinal symptoms and epilepsy are presented, and serious symptoms of consciousness confusion, loss of orientation force, hallucinations, anxiety, insomnia and the like are presented. Alcohol dependence brings great harm to society and families, and at present, the alcohol dependence and related problems are the third global public health problem after cardiovascular diseases and tumors. The great cost of abstinence and the treatment of abstinence syndrome every year brings great economic loss to patients. Therefore, such diseases should be highly regarded.
The current drugs for treating alcohol withdrawal syndrome mainly comprise abstinence sulfur, acamprosate, naltrexone and the like, and although the drugs are approved by the FDA in the United states for clinical use, the drugs mainly act on a reward system for exciting alcohol dependence and prevent the formation of alcohol addiction. However, the use of these drugs for the treatment of alcohol addiction and withdrawal syndrome has limited efficacy and significant side effects, such as liver damage and central neurotoxicity associated with alcohol withdrawal. Therefore, it is necessary to develop a novel drug with high efficiency, small side effect and convenient use for treating alcohol withdrawal syndrome. The applicant researches and discovers that intestinal microorganisms play an important role in the formation of alcohol dependence, and drinking alcohol can induce the imbalance of intestinal flora and lead to the increase of intestinal wall permeability, so that some metabolites of bacteria such as short-chain fatty acid, amine and some neurotransmitters directly or indirectly act on the central nervous system through an intestinal-brain-axis to cause dependence diseases including alcohol dependence. Therefore, the invention starts from the action mechanism of intestinal microbial balance, develops a novel prebiotics and probiotic compound, and is used for adjusting the imbalance of intestinal flora caused by alcohol and alcohol withdrawal so as to relieve and treat the alcohol withdrawal syndrome.
Disclosure of Invention
The invention aims to provide a probiotic compound preparation for treating alcohol withdrawal syndrome and a preparation method thereof.
In order to achieve the purpose, the invention adopts the technical scheme that: a preparation method of a probiotic compound preparation for treating alcohol withdrawal syndrome comprises the following steps:
respectively inoculating clostridium butyricum, lactobacillus acidophilus, lactobacillus plantarum and bifidobacterium into respective optimal culture medium, culturing for 24 hours at 37 ℃, respectively taking 150mL of culture solution to transfer into a fermentation tank for expanded culture, and when the concentration of viable bacteria in fermentation liquor reaches 5 multiplied by 109Stopping culturing when the concentration is above CFU/ml, centrifuging the fermentation liquor at 4000 rpm for 20 minutes, and collecting thalli;
uniformly mixing clostridium butyricum, lactobacillus acidophilus, lactobacillus plantarum and bifidobacterium collected in the step one according to the weight ratio of 2-3: 1: 1.5-2: 1-2 to obtain a probiotic mixture;
mixing the probiotic mixture and an adsorption carrier according to the weight ratio of 1: 2-3, and stirring at the temperature of not higher than 10 ℃ to enable thalli to be completely adsorbed on the adsorption carrier;
mixing the mixture prepared in the step III with prebiotics according to the weight ratio of 1: 1.5-5, and stirring uniformly at room temperature;
fifthly, adding the mixture prepared in the step (iv) into the coating carrier solution according to the volume ratio of 1: 10-20, continuing stirring for 30 minutes, ventilating and drying at room temperature, and packaging to obtain the coating carrier solution.
Preferably, the prebiotics are composed of any one or more of galacto-oligosaccharides (GOS), inulin, stachyose and chitosan.
Preferably, the adsorption carrier is one or more of bran, corn starch, skimmed milk powder, zeolite powder, sucrose and sodium alginate.
Preferably, the coating carrier is one or two of sucrose and dextrin.
Preferably, the concentration of the coating carrier solution is 5 to 10% (mass concentration).
The invention has the following beneficial effects: 1. the invention aims to provide a compound prebiotics and probiotic preparation for treating alcohol withdrawal syndrome, and the medicine is a compound microecological preparation. 2. The preferable probiotics of the invention are common nonpathogenic dominant bacteria of human body, the bacteria can be planted in intestinal tracts of human body and proliferate in large quantity, the intestinal micro-ecological environment is improved by the action of dominant bacteria, biological antagonism, production of beneficial metabolite, direct stimulation of intestinal mucosa epithelium and the like, and the bacteria act on brain through 'intestine-brain-axis', thus achieving the purpose of relieving and treating alcohol dependence syndrome. 3. The invention adopts a unique three-layer coating process, the outermost layer is a carrier protective layer which can prevent the probiotics from being killed by harmful substances in vivo and in vitro, and particularly can prevent the probiotics from entering the stomach and being damaged by gastric acid and protease, so as to reach the intestinal tract to play a role; in the intestine, the second prebiotic layer provides a suitable living environment for the probiotics in the intestine, and the probiotics can be greatly added to play a role. 4. The unique coating process can prolong the storage life of the activity of the probiotics, overcome the defect of short storage life of the conventional probiotic products, and effectively resist the influence of alcohol in vivo on the probiotics caused by drinking.
Drawings
FIG. 1 shows the withdrawal syndrome scores of different groups of alcohol-dependent rats in test one;
FIG. 2 shows the withdrawal syndrome scoring results of different groups of alcohol-dependent mice in test two.
Detailed Description
The invention is further illustrated with reference to specific examples, but the scope of the invention is not limited thereto. The clostridium butyricum, lactobacillus acidophilus, lactobacillus plantarum and bifidobacterium used in the invention are all conventional commercial strains.
Example 1
A preparation method of a probiotic compound preparation for treating alcohol withdrawal syndrome comprises the following steps:
respectively inoculating clostridium butyricum, lactobacillus acidophilus, lactobacillus plantarum and bifidobacterium into respective optimal culture medium, culturing for 24 hours at 37 ℃, respectively taking 150mL of culture solution to transfer into a fermentation tank for expanded culture, and when the concentration of viable bacteria in fermentation liquor reaches 5 multiplied by 109Stopping culturing when the concentration is above CFU/ml, centrifuging the fermentation liquor at 4000 rpm for 20 minutes, and collecting thalli;
uniformly mixing clostridium butyricum, lactobacillus acidophilus, lactobacillus plantarum and bifidobacterium collected in the step I according to the weight ratio of 2: 1: 1.5: 2 to obtain a probiotic mixture;
mixing the probiotic mixture and an adsorption carrier according to the weight ratio of 1: 3, and stirring at the speed of 75 revolutions per minute for 25 minutes in the environment of 10 ℃ to ensure that thalli are completely adsorbed on the carrier; the adsorption carrier is composed of the following raw materials in parts by weight: 50 parts of bran, 200 parts of skim milk powder, 30 parts of cane sugar and 20 parts of sodium alginate;
mixing the mixture prepared in the step (III) with prebiotics according to the weight ratio of 1: 3.33, and stirring at the speed of 50 revolutions per minute for 30 minutes at room temperature; the prebiotics are composed of the following raw materials in parts by weight: 30 parts of galacto-oligosaccharides (GOS), 15 parts of inulin and 20 parts of stachyose;
fifthly, adding the mixture prepared in the step (iv) into a coating carrier solution (the coating carrier solution contains 5wt% of dextrin and 2wt% of cane sugar) according to the volume ratio of 1: 20, continuously stirring for 30 minutes at the speed of 100 revolutions per minute, ventilating and drying at room temperature, and packaging to obtain the finished product.
Example 2
A preparation method of a probiotic compound preparation for treating alcohol withdrawal syndrome comprises the following steps:
firstly, clostridium butyricum, lactobacillus acidophilus and lactobacillus plantarum are mixedRespectively inoculating Bifidobacterium into respective optimum culture medium, culturing at 37 deg.C for 24 hr, respectively taking 150mL of culture solution, transferring into fermentation tank for amplification culture, and when viable bacteria concentration in the fermentation broth reaches 5 × 109Stopping culturing when the concentration is above CFU/ml, centrifuging the fermentation liquor at 4000 rpm for 20 minutes, and collecting thalli;
uniformly mixing clostridium butyricum, lactobacillus acidophilus, lactobacillus plantarum and bifidobacterium collected in the step I according to the weight ratio of 3: 1: 2: 1 to obtain a probiotic mixture;
mixing the probiotic mixture and an adsorption carrier according to the weight ratio of 1: 2.1, and stirring at the speed of 175 revolutions per minute for 25 minutes in the environment of 10 ℃ to ensure that thalli are completely adsorbed on the carrier; the adsorption carrier is composed of the following raw materials in parts by weight: 150 parts of bran, 100 parts of skim milk powder, 20 parts of cane sugar and 40 parts of sodium alginate;
mixing the mixture prepared in the step (III) with prebiotics according to the weight ratio of 1: 1.6, and stirring at the speed of 100 revolutions per minute for 20 minutes at room temperature; the prebiotics are composed of the following raw materials in parts by weight: 20 parts of galacto-oligosaccharide (GOS), 45 parts of inulin, 10 parts of stachyose and 20 parts of chitosan;
fifthly, adding the mixture prepared in the step (iv) into a coating carrier solution (containing 6wt% of dextrin and 3wt% of sucrose) according to the volume ratio of 1: 10, continuously stirring for 30 minutes at the speed of 100 revolutions per minute, ventilating and drying at room temperature, and packaging to obtain the product.
Example 3
Example 3 differs from example 1 in that the weight ratio of the bacteria of Clostridium butyricum, Lactobacillus acidophilus, Lactobacillus plantarum and Bifidobacterium in step (ii) is 1: 1.
The influence of the drug of the invention on alcohol addiction in the alcohol withdrawal syndrome of rats (test one)
1. Experimental animals: sprague Dawley (SD) rats 60 weeks old, initial body weights (190-.
Establishing an alcohol dependence model: the groups were divided into 2 groups, a control group (20) and an experimental group (40) according to a completely random method. Animals were housed in a clean animal house at 21 + -2 deg.C and 50 + -5% humidity, and experiments were performed after 1 week of acclimatization. During the experiment, rats in each group were fed freely, and the feed was SPF-grade and purchased from kyoto australia, co-tech ltd. The rats were given free alcohol in 1%, 2%, 3%, 4%, 5%, 6% increments (1% increments per day, 6% also on the seventh day) for the first week of the experimental group, and were given 6% (v/v) alcohol-water solution for 24h for 6 weeks from the second week, and the alcohol-water solution was prepared and replaced at 9 o' clock per day; controls were given tap water for drinking. From week 7, the experimental group was deprived of alcohol and divided into two groups, one group was withdrawal group (20), tap water was administered alone, the other group was withdrawal group (20), tap water plus the probiotic composite formulation of example 1 of the present invention was administered at a dose of 5 g/day/one, and the administration was continued for 10 days.
Alcohol withdrawal syndrome score: alcohol Withdrawal Syndrome (EWS) scoring the Withdrawal syndromes of the Withdrawal group Rats were evaluated on days 1, 3, 5 AND 9, respectively, by reference to the improved Erden et al (1999) method, mainly to detect the occurrence of Withdrawal symptoms such as stereotypical Behavior, irritability, rigidity of the tail, abnormal posture AND auditory epilepsy, all tests were selected at 9:00 am to ensure the accuracy of the test results, AND double blind experiments, detailed scoring criteria references (b.f. Erden, s.oz. heirci, g.yildran, t.utn, n.gagadand g. ULAK, 1999, dextran attentuated animals witha Syndrome in Rats, biochemical Biochemistry, behav, 62, 541) were used.
Statistical analysis: all data are expressed as x +/-S, statistical analysis is carried out by adopting SPSS 19.0 software, and two groups of comparison adopts t test; the comparisons between groups were analyzed using One-Way ANOVA.
Results of the experiment
5.1 withdrawal scoring results: in the study, a rat model of alcohol dependence is established by freely drinking 6% alcohol, alcohol withdrawal syndrome indexes are determined by a double-blind detection method, and the result shows that the alcohol withdrawal scores of a drinking group are obviously different from those of a control group (figure 1). The alcohol dependence increased in the experimental group after withdrawal, with the highest withdrawal score occurring at 3 days of withdrawal. There was no significant difference in total withdrawal scores after 9 days of withdrawal compared to the control group. However, after the probiotic compound preparation of the invention 1 is used, the alcohol withdrawal group and the withdrawal intervention group have no significant difference in the first three days, but after the 5 th day, the withdrawal group and the withdrawal intervention group have significant difference, and the probiotic compound preparation of the invention 1 reaches the level of the control group in the 5 th day (figure 1), which shows that the probiotic compound preparation of the invention has good curative effect on alcohol dependence syndrome.
Audiogenic epilepsy outcomes: the stimulation was performed with 100 db sound for 1 minute, and the results are shown in table 1. The incidence rate of the auditory epilepsy of the first day alcohol dependence withdrawal group reaches 80 percent, while the incidence rate of the auditory epilepsy of the control group is only 10 percent, and the results show that the long-term drinking of the 6 percent alcohol can cause the body dependence of the rats. However, the withdrawal group and the withdrawal intervention group have no significant difference on the first day of withdrawal, from the third day, the incidence rate of the auditory epilepsy can be greatly reduced after the drug is used for intervention prognosis, the incidence rate of the auditory epilepsy is reduced to 15% on the fifth day, and the incidence rate of the auditory epilepsy of rats without the drug is 65%. Therefore, the probiotic compound preparation disclosed by the embodiment 1 can greatly reduce the incidence rate of the audiogenic epilepsy of the alcohol-dependent rat.
TABLE 1 incidence of audiogenic epilepsy
The influence of the drug of the invention on the alcohol withdrawal syndrome of mice with chronic alcohol addiction (test two)
1. Experimental animals: 60 BALB/c mice at 6 weeks of age, initial body weights (19-25 g), purchased from Beijing Unilihua, animal No. SCXK (tying) 2017-0014 (No. 11000830258653).
Establishing an alcohol dependence model: the groups were divided into 2 groups, a control group (15) and an experimental group (45) according to a completely random method. Animals were housed in a clean animal house at 21 + -2 deg.C and 50 + -5% humidity, and experiments were performed after 1 week of acclimatization. During the experiment, each group of mice was fed freely, and the feed was SPF-grade and purchased from kyoto australia, co-tech ltd. Mice were given free alcohol for the first week in 1%, 2%, 3%, 4%, 5%, 6% increments (1% increments per day, 6% increments also for the seventh day), and then were given free alcohol containing low concentration ethanol (6%) for 6 weeks (9 o' clock per day to prepare and replace aqueous alcohol) to establish alcohol-dependent animal models. Tap water was given as a control. From week 7, the experimental group was deprived of alcohol and divided into three groups, one group was withdrawal group (15) to which tap water alone was administered, and the second group was withdrawal group I (15) to which tap water plus the probiotic composite formulation of example 2 of the present invention was administered at a dose of 5 g/day for 10 days; the third group was abstinence arm group II (15), which was given tap water and probiotic combination formulation of example 3 of the present invention.
Alcohol withdrawal syndrome score: alcohol Withdrawal Syndrome (EWS) scoring the Withdrawal syndromes of the Withdrawal group mice were evaluated on days 1, 3, 5 AND 9 of alcohol Withdrawal, respectively, by reference to the improved Erden et al (1999) method, mainly to detect the occurrence of Withdrawal symptoms such as stereotypical Behavior, irritability, rigidity of the tail, abnormal posture AND auditory epilepsy, all tests were selected at 9:00 am to ensure the accuracy of the test results, AND double blind experiments, detailed scoring criteria references (b.f. Erden, s.oz. demirci, g.yildran, t.utkan, n.gaand car g.ulak, 1999, dextran attentuites ethyl alcohol Withdrawal Syndrome in Rats, pharmacological Biochemistry, behav, 62, 537) were used.
Statistical analysis: all data are expressed as x +/-S, statistical analysis is carried out by adopting SPSS 19.0 software, and two groups of comparison adopts t test; the comparisons between groups were analyzed using One-Way ANOVA.
Results of the experiment
5.1 withdrawal scoring results: in the study, an alcohol dependence mouse model is established by freely drinking 6% alcohol, alcohol withdrawal syndrome indexes are determined by a double-blind detection method, and the result shows that the alcohol withdrawal scores of a drinking group are obviously different from those of a control group (figure 2). The alcohol dependence increased in the experimental group after withdrawal, with the highest withdrawal score occurring at 3 days of withdrawal. There was no significant difference in total withdrawal scores after 9 days of withdrawal compared to the control group. After the medicine is used, the alcohol withdrawal group and the withdrawal intervention group have no significant difference in the first three days, but the alcohol withdrawal group and the withdrawal intervention group have significant difference after the 5 th day, and the alcohol withdrawal group and the withdrawal intervention group reach the level of a control group (figure 2) after the 5 th day of the withdrawal, which shows that the probiotic prebiotic preparation has good curative effect on alcohol dependence syndrome; meanwhile, compared with the withdrawal intervention group II, in the withdrawal intervention group II, although the probiotic compound preparation of the embodiment 3 is used, the effect is poorer, the withdrawal symptoms and the withdrawal group are similar in the whole experimental period, but the effect is obviously different from that of the withdrawal intervention group I, and different proportions of clostridium butyricum, lactobacillus acidophilus, lactobacillus plantarum and bifidobacterium have obvious influence on the effect of the probiotic compound preparation of the invention.
Audiogenic epilepsy outcomes: the stimulation was performed with 100 db sound for 1 minute, and the results are shown in table 2. The incidence rate of the auditory epilepsy of the first day alcohol dependence withdrawal group reaches 86.67 percent, while the incidence rate of the control group is only 13.34 percent, and the results show that the long-term drinking of the 6 percent alcohol can cause the physical dependence of the rats. However, the withdrawal group and the withdrawal intervention group have no significant difference on the first day of withdrawal, from the third day, the incidence rate of the auditory epilepsy can be greatly reduced after the drug is used for intervention prognosis, and the incidence rate of the auditory epilepsy is reduced to 20% in the fifth day, while the incidence rate of the auditory epilepsy of rats without the drug is 73.33%. Meanwhile, from the result of the withdrawal intervention group I, the adoption of the probiotic compound preparation can obviously improve the alcohol dependence symptom, and therefore, the probiotic compound preparation in the embodiment 2 of the invention can greatly reduce the incidence rate of the audible epilepsy of the alcohol dependence rat.
TABLE 2 incidence of audiogenic epilepsy
Claims (6)
1. A preparation method of a probiotic compound preparation for treating alcohol withdrawal syndrome is characterized by comprising the following steps:
respectively inoculating clostridium butyricum, lactobacillus acidophilus, lactobacillus plantarum and bifidobacterium into respective optimal culture medium, culturing for 24-48 hours at 37 ℃, taking culture solution and transferring the culture solution into a fermentation tank for expanded culture, and when the concentration of viable bacteria in fermentation liquor reaches 5 multiplied by 109Stopping culturing when the concentration is above CFU/ml, centrifuging the fermentation liquor, and collecting thalli;
uniformly mixing clostridium butyricum, lactobacillus acidophilus, lactobacillus plantarum and bifidobacterium collected in the step one according to the weight ratio of 2-3: 1: 1.5-2: 1-2 to obtain a probiotic mixture;
mixing the probiotic mixture and an adsorption carrier according to the weight ratio of 1: 2-3, and stirring to enable thalli to be completely adsorbed on the adsorption carrier;
mixing the mixture prepared in the step III with prebiotics according to the weight ratio of 1: 1.5-5, and stirring uniformly at room temperature;
fifthly, adding the mixture prepared in the step (iv) into the coating carrier solution according to the volume ratio of 1: 10-20, uniformly stirring, ventilating and drying at room temperature, and packaging to obtain the coating carrier solution.
2. The method for preparing a probiotic compound preparation for the treatment of alcohol withdrawal syndrome as claimed in claim 1, wherein said prebiotics are comprised of any one or more of galacto-oligosaccharide GOS, inulin, stachyose and chitosan.
3. The method for preparing a probiotic compound preparation for treating alcohol withdrawal syndrome as claimed in claim 1, wherein the adsorption carrier is any one or more of bran, corn starch, skimmed milk powder, zeolite powder, sucrose, and sodium alginate.
4. The method for preparing the probiotic composite preparation for treating alcohol withdrawal syndrome according to claim 1, wherein: the coating carrier is one or two of sucrose and dextrin.
5. The method for preparing the probiotic composite preparation for treating alcohol withdrawal syndrome according to claim 1, wherein: the concentration of the coating carrier solution is 5-10 wt%.
6. A probiotic combination preparation for use in the treatment of alcohol withdrawal syndrome, prepared by the process according to any one of claims 1 to 5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810900031 | 2018-08-09 | ||
| CN2018109000310 | 2018-08-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109350629A CN109350629A (en) | 2019-02-19 |
| CN109350629B true CN109350629B (en) | 2021-06-01 |
Family
ID=65345365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811356719.3A Active CN109350629B (en) | 2018-08-09 | 2018-11-15 | Probiotic compound preparation for treating alcohol withdrawal syndrome and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109350629B (en) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614225A (en) * | 2011-01-28 | 2012-08-01 | 湖北国力生物技术开发有限公司 | Composite active probiotic preparation and its industrial production method |
| US9161957B2 (en) * | 2012-08-03 | 2015-10-20 | Life Well Lived, Llc | Compositions and methods for reducing blood alcohol content |
| CN106456679A (en) * | 2013-05-10 | 2017-02-22 | 百通生物技术公司 | Compositions comprising mixture of bacteria comprising pedoiococcus and lactobacillus methods for decreasing effects of alcohols |
| MA41020A (en) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME |
| CN104940240B (en) * | 2015-08-04 | 2016-08-24 | 王玫璇 | A kind of probiotics preparation for relieving alcoholism and protecting the liver and its preparation method and application |
| CN106434489B (en) * | 2016-11-18 | 2021-04-30 | 中国人民解放军疾病预防控制所 | High-yield wine Klebsiella pneumoniae strain and application thereof |
| CN108203702A (en) * | 2016-12-20 | 2018-06-26 | 北京中科星冠生物技术股份有限公司 | A kind of compound probiotic alcohol-decomposing beverage and its specific complex probiotics |
| CN106867930B (en) * | 2016-12-29 | 2020-05-19 | 大连医科大学 | Lactobacillus plantarum PLH1405 and application thereof in preparation of medicine for treating acute alcohol poisoning |
| CN108208853B (en) * | 2018-01-04 | 2021-03-26 | 山东凤凰生物有限公司 | Probiotic oligopeptide compound preparation for dispelling effects of alcohol and protecting liver and preparation method thereof |
-
2018
- 2018-11-15 CN CN201811356719.3A patent/CN109350629B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109350629A (en) | 2019-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3066561C (en) | Compositions comprising a bacterial strain of the genus megasphera and uses thereof | |
| US20150037286A1 (en) | Use of roseburia in the prevention and treatment for obesity related diseases | |
| EP3600363B1 (en) | Compositions comprising bacterial strains | |
| TW202038979A (en) | Compositions comprising bacterial strains | |
| EA035949B1 (en) | Use of a composition comprising bacterial blautia hydrogenotrophica strain and method of treating or preventing visceral hypersensitivity | |
| US10443033B2 (en) | Lactobacillus rhamnosus RHT-3201 (KCTC 10833BP) conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| CN106974262B (en) | Application of intestinal probiotic bacillus in treating and preventing obesity and related diseases | |
| TW202034776A (en) | Bifidobacterium longum subsp Longum, composition containing bifidobacterium longum subsp Longum and application | |
| JP7531865B2 (en) | Discovery of a novel Akkermansia muciniphila AK32 strain and its application for the prevention or treatment of intestinal damage | |
| AU2019201637A1 (en) | Compositions Comprising a Mixture of Bacteria Comprising Pediococcus and Lactobacillus and Methods for Decreasing the Effects of Alcohols | |
| WO2020113579A1 (en) | Use of megamonas funiformis in prevention and/or treatment of metabolic diseases | |
| US20210085730A1 (en) | USE OF BUTYRlBACTER INTESTINI IN PREVENTING AND/OR TREATING INFLAMMATION-RELATED DISEASES | |
| CN109350629B (en) | Probiotic compound preparation for treating alcohol withdrawal syndrome and preparation method thereof | |
| US20190070204A1 (en) | Proliferative agent for faecalibacterium | |
| WO2018107365A1 (en) | Anaerostipes caccae and applications thereof | |
| CN117448198A (en) | Bifidobacterium animalis subspecies VB301 and application thereof | |
| US20150296850A1 (en) | Use of polysaccharides for the intestinal well-being of nursing infants and/or infants | |
| CN114081184B (en) | Probiotic capable of preventing depression and anxiety behavior formation and application thereof | |
| CN115537356A (en) | Compound probiotic with effect of preventing or relieving blood pressure increase and preparation method and application thereof | |
| CN117122620B (en) | Use of AKKERMANSIA MUCINIPHILA in the preparation of a product for the prevention, treatment and/or adjuvant treatment of arthritis | |
| CN116606761B (en) | Bifidobacterium animalis subspecies BLa19 capable of relieving rheumatoid arthritis and application thereof | |
| CN113355253B (en) | Bifidobacterium animalis and application thereof | |
| Favaron et al. | The Ageing Microbiome, Pharmaceutical Considerations, and Therapeutic Opportunities | |
| CN117814304A (en) | Preparation method and application of intestinal microecological active liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |